175 related articles for article (PubMed ID: 25983032)
1. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma.
Zhang W; Chen H; Lv S; Yang H
Mol Neurobiol; 2016 May; 53(4):2354-60. PubMed ID: 25983032
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.
Han M; Guo L; Zhang Y; Huang B; Chen A; Chen W; Liu X; Sun S; Wang K; Liu A; Li X
Mol Neurobiol; 2016 Jan; 53(1):720-727. PubMed ID: 25589004
[TBL] [Abstract][Full Text] [Related]
3. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.
Qin G; Li X; Chen Z; Liao G; Su Y; Chen Y; Zhang W
Mol Neurobiol; 2017 Jul; 54(5):3264-3270. PubMed ID: 27090900
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
Zhong C; Wu JD; Fang MM; Pu LY
Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
8. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
9. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.
Huang R; Mo D; Wu J; Ai H; Lu Y
Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012
[TBL] [Abstract][Full Text] [Related]
10. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
[TBL] [Abstract][Full Text] [Related]
11. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD133 as a Putative Prognostic Biomarker to Predict Intracranial Dissemination of Primary Spinal Cord Astrocytoma.
Inoue T; Endo T; Nakamura T; Shibahara I; Endo H; Tominaga T
World Neurosurg; 2018 Feb; 110():e715-e726. PubMed ID: 29180077
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma.
Park YY; An CH; Oh ST; Chang ED; Lee J
Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.
Pallini R; Ricci-Vitiani L; Banna GL; Signore M; Lombardi D; Todaro M; Stassi G; Martini M; Maira G; Larocca LM; De Maria R
Clin Cancer Res; 2008 Dec; 14(24):8205-12. PubMed ID: 19088037
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis.
Zhai JH; Gu WC; Xu XL; Wu J; Hu XJ; Hou KZ
Tumour Biol; 2015 Feb; 36(2):701-9. PubMed ID: 25286754
[TBL] [Abstract][Full Text] [Related]
16. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.
Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J
Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892
[TBL] [Abstract][Full Text] [Related]
18. CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma.
Lee SY; Kim JK; Jeon HY; Ham SW; Kim H
Mol Cells; 2017 Jul; 40(7):515-522. PubMed ID: 28736425
[TBL] [Abstract][Full Text] [Related]
19. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of microRNA-21 expression in gliomas: a meta-analysis.
Li C; Sun J; Xiang Q; Liang Y; Zhao N; Zhang Z; Liu Q; Cui Y
J Neurooncol; 2016 Oct; 130(1):11-17. PubMed ID: 27531352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
